Callisto Pharmaceuticals, Inc.

Intellectual property department created at pharma firm to expand new drug pipeline

Published in Pharma Law Weekly, January 17th, 2006

Callisto Pharmaceuticals, Inc., (KAL) announced the formation of a Department of Intellectual Property to spearhead growth of the company's pipeline of new drug candidates, while broadening protection of its intellectual property portfolio through creation of multiple patents around broad classes of new drugs, as well as narrowly-focused claims on specific compounds.

Callisto has named David Ladner, a patent agent and research scientist with extensive background in the pharmaceutical and chemical industries, to head the unit in the position of director of Intellectual Property.

"The robust expansion of our intellectual property portfolio is a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2006-01-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry